Cinclus Pharma Holding AB (publ) (STO:CINPHA)
12.26
+0.24 (2.00%)
At close: Jul 23, 2026
Cinclus Pharma Holding AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 475.85 | 487.25 | 566.72 | 87.97 | 173.55 | 138.2 |
Cash & Short-Term Investments | 475.85 | 487.25 | 566.72 | 87.97 | 173.55 | 138.2 |
Cash Growth | -9.17% | -14.02% | 544.20% | -49.31% | 25.57% | -33.72% |
Accounts Receivable | 1.42 | 16.06 | - | - | - | - |
Other Receivables | 4.06 | 4.99 | 1.94 | - | 5.1 | 1.38 |
Total Trade Receivables | 5.48 | 21.05 | 1.94 | - | 5.1 | 1.38 |
Other Current Assets | 21.46 | 28.55 | 31.81 | 6.12 | 6.24 | 5.77 |
Total Current Assets | 502.79 | 536.85 | 600.47 | 94.09 | 184.88 | 145.36 |
Net Property, Plant & Equipment | 7.57 | 9.41 | 0.54 | 0.25 | 0.89 | 1.82 |
Other Long-Term Assets | 1.29 | 0.3 | 0 | 0.07 | 0 | 0 |
Total Assets | 511.64 | 546.56 | 601.01 | 94.41 | 185.77 | 147.18 |
Accounts Payable | 29.52 | 48.46 | 18.93 | 16.45 | 16.95 | 9.19 |
Accrued Expenses | 23.21 | 20.83 | 16.9 | 6.83 | 20.47 | 7.51 |
Short-Term Debt | 45.79 | - | - | 130.34 | - | - |
Current Portion of Leases | 3.17 | 3.11 | 0.11 | 0.02 | 0.54 | 0.85 |
Unearned Revenue | 35.71 | 54.53 | - | - | - | - |
Other Current Liabilities | 36.56 | 9.86 | 9.56 | 10.78 | 8.14 | 1.92 |
Total Current Liabilities | 173.96 | 136.79 | 45.49 | 164.42 | 46.1 | 19.47 |
Long-Term Leases | 3.96 | 4.79 | 0.19 | - | - | 0.61 |
Other Long-Term Liabilities | 52.67 | 35.59 | - | 6.79 | 12.8 | - |
Total Long-Term Liabilities | 56.63 | 40.37 | 0.19 | 6.79 | 12.8 | 0.61 |
Total Liabilities | 230.59 | 177.17 | 45.68 | 171.21 | 58.9 | 20.08 |
Common Stock | 0.92 | 0.92 | 0.92 | 0.51 | 0.51 | 0.26 |
Additional Paid-in Capital | 1,298 | 1,298 | 1,298 | 503.52 | 503.69 | 276.74 |
Accumulated Other Comprehensive Income | 23.71 | 23.53 | 28.67 | 26 | 16.84 | -4.82 |
Retained Earnings | -1,041 | -952.8 | -772 | -606.84 | -394.16 | -145.08 |
Shareholders' Equity | 281.05 | 369.39 | 555.33 | -76.8 | 126.87 | 127.1 |
Total Liabilities & Equity | 511.64 | 546.56 | 601.01 | 94.41 | 185.77 | 147.18 |
Total Debt | 52.93 | 7.9 | 0.3 | 130.37 | 0.54 | 1.46 |
Net Cash (Debt) | 422.92 | 479.36 | 566.42 | -42.39 | 173 | 136.75 |
Net Cash Growth | -19.21% | -15.37% | - | - | 26.51% | -34.41% |
Net Cash Per Share | 9.08 | 10.29 | 15.28 | -1.62 | 7.51 | 6.48 |
Book Value | 281.05 | 369.39 | 555.33 | -76.8 | 126.87 | 127.1 |
Book Value Per Share | 6.04 | 7.93 | 14.98 | -2.93 | 5.51 | 6.03 |
Tangible Book Value | 281.05 | 369.39 | 555.33 | -76.8 | 126.87 | 127.1 |
Tangible Book Value Per Share | 6.04 | 7.93 | 14.98 | -2.93 | 5.51 | 6.03 |